MARKETS
Earnings

UPDATE: Vor Biopharma Q2 Adj. EPS $(0.80) Misses $(0.70) Estimate

Aug 11, 2026 · 05:30 PM ET· updated 58m ago

Vor Biopharma (NASDAQ:VOR) reported quarterly losses of $(0.80) per share which missed the analyst consensus estimate of $(0.70) by 14.29 percent. This is a 98.17 percent increase over losses of $(43.80) per share from

Share
Why It Matters

Vor Biopharma lost more money per share than experts thought it would. When a company loses more than expected, it can mean they're spending faster than planned, so it's worth watching how long their money lasts.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.